Effect of prophylactic supplementation with grape polyphenolics on endotoxin-induced serum secretory phospholipase A2 activity in rats

Comparative Medicine

Volumn 62, Issue 4, 2012, Pages 271-278

  Tsao, Francis H C ^a   Culver, Bryan J ^a   Pierre, Joseph F ^a,b   Shanmuganayagam, Dhanansayan ^b   Patten, Calvin C ^a   Meye, Keith C ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ENDOTOXIN; GRAPE SEED EXTRACT; LIPOPOLYSACCHARIDE; PHOSPHOLIPASE A2; POLYPHENOL DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BIOASSAY; BODY WEIGHT; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FLUOROMETRY; HEALTH STATUS; HEMATOCRIT; INFLAMMATION; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; RAT; SPRAGUE DAWLEY RAT;

EID: 84870590943     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. 2. Biochim Biophys Acta 1502:257-263.
2. Bascands JL, Bachvarova M, Neau E, Schanstra JP, Bachvarov D. 2009. Molecular determinants of LPS-induced acute renal inflam-mation: implication of the kinin B1 receptor. Biochem Biophys Res Commun 386:407-412.
3. Baumann H, Gauldie J. 1994. The acute-phase response. Immunol Today 15:74-80.
4. Biesalski HK. 2007. Polyphenols and inflammation: basic interactions. Curr Opin Clin Nutr Metab Care 10:724-728. (Pubitemid 350293773)
5. Blanque R, Meakin C, Millet S, Gardner CR. 1998. Selective enhancement of LPS-induced serum TNFα production by carrageenan pretreatment in mice. Gen Pharmacol 31:301-306. (Pubitemid 28288408)
6. Bulger EM, Maier RV. 2000. Lipid mediators in the pathophysiology of critical illness. Crit Care Med 28:N27-N36.
7. 2 biochemistry. Cardio-vasc Drugs Ther 23:49-59.
8. Danesh J, Collins R, Appleby P, Peto R. 1998. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. J Am Med Assoc 279:1477-1482. (Pubitemid 28228207)
9. 2 and lysophosphatidylcholine in the mediation of LPS-induced gastric injury. Shock 33:634-638.
10. Dinges MM, Schlievert PM. 2001. Comparative analysis of lipopolysaccharide-induced tumor necrosis factor α activity in serum and lethality in mice and rabbits pretreated with the staphylococcal superantigen toxic shock syndrome toxin 1. Infect Immun 69:7169-7172. (Pubitemid 32995481)
11. Endo Y, Shibazaki M, Yamaguchi K, Kai K, Sugawara S, Takada H, Kikuchi H, Kumagai K. 1999. Enhancement by galactosamine of lipopolysaccharide (LPS)-induced tumour necrosis factor production and lethality: its suppression by LPS pretreatment. Br J Pharmacol 128:5-12. (Pubitemid 29425261)
12. Gentry PA. 1999. Acute-phase proteins, p 336-398. In: Loeb WF, Quimby FW, editors. The clinical chemistry of laboratory animals. Philadelphia (PA): Taylor and Francis.
13. 2 in rodents during inflammation. Biochim Biophys Acta 1635:37-47.
14. Hogan S, Canning C, Sun S, Sun X, Kadouh H, Zhou K. 2011. Dietary supplementation of grape skin extract improves glycemia and inflammation in diet-induced obese mice fed a Western high-fat diet. J Agric Food Chem 59:3035-3041.
15. Hogan S, Canning C, Sun S, Sun X, Zhou K. 2010. Effects of grape pomace antioxidant extract on oxidative stress and inflammation in diet-induced obese mice. J Agric Food Chem 58:11250-11256.
16. 2 released from rat platelets. J Biochem 101:625-631.
17. 2 in mononuclear phagocytic cells in rat spleen and liver. Eur J Biochem 197:323-329.
18. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. 2005. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81:230S-242S.
19. 2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins Other Lipid Mediat 79:1-33.
20. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW. 1988. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481-1486.
21. 2 from activated mast cells and its possible involvement in the regulation of the degranulation process. Eur J Biochem 209:257-265.
22. Nevalainen TJ, Eerola LI, Rintala E, Laine VJ, Lambeau G, Gelb MH. 2005. Time-resolved fluoroimmunoassays of the complete set of secreted phospholipases A2 in human serum. Biochim Biophys Acta 1733:210-223. (Pubitemid 40603664)
23. 2. [Review] Biochim Biophys Acta 1781:1-9.
24. 2 in the human gastrointestinal tract. Lab Invest 72:201-208.
25. 2 in inflammatory diseases and trauma. Biochim Biophys Acta 1488:83-90.
26. Nevalainen TJ, Haapanen TJ. 1993. Distribution of pancreatic (group I) and synovial-type (group II) phospholipases A2 in human tissues. Inflammation 17:453-464. (Pubitemid 23217570)
27. 2 protein and mRNA in rat tissues. J Histochem Cytochem 48:1469-1478.
28. Obrenovich ME, Nair NG, Beyaz A, Aliev G, Reddy VP. 2010. The role of polyphenolic antioxidants in health, disease, and aging. Rejuvenation Res 13:631-643.
29. Pandey KB, Rizvi SI. 2009. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev 2:270-278.
30. Pappas P, Sotiropoulou M, Karamanakos P, Kostoula A, Levidiotou S, Marselos M. 2003. Acute-phase response to benzo[a]pyrene and induction of rat ALDH3A1. Chem Biol Interact 143-144:55-62. (Pubitemid 36258339)
31. Pepys MB, Hirschfield GM. 2003. C-reactive protein: a critical update. J Clin Invest 111:1805-1812. (Pubitemid 38057722)
32. 2 secretion of the murine small intestine. JPEN J Parenter Enteral Nutr 35:748-756.
33. Povoa P. 2002. C-reactive protein: a valuable marker of sepsis. Intensive Care Med 28:235-243. (Pubitemid 34230643)
34. 2 activity by intravenous infusion of endotoxin in patients with neoplasia. J Immunother 12:242-246.
35. Rasmussen SE, Frederiksen H, Struntze Krogholm K, Poulsen L. 2005. Dietary proanthocyanidins: occurrence, dietary intake, bioavailability, and protection against cardiovascular disease. Mol Nutr Food Res 49:159-174. (Pubitemid 40379813)
36. Rathee P, Chaudhary H, Rathee S, Rathee D, Kumar V, Kohli K. 2009. Mechanism of action of flavonoids as antiinflammatory agents: a review. Inflamm Allergy Drug Targets 8:229-235.
37. Rintala EM, Aittoniemi J, Laine S, Nevalainen TJ, Nikoskelainen J. 2001. Early identification of bacteremia by biochemical markers of systemic inflammation. Scand J Clin Lab Invest 61:523-530. (Pubitemid 33702359)
38. Rodrigo R, Miranda A, Vergara L. 2011. Modulation of endogenous antioxidant system by wine polyphenols in human disease. Clin Chim Acta 412:410-424.
39. Ruggiero V, D'Urso CM, Albertoni C, Campo S, Foresta P, Martelli EA. 1993. LPS-induced serum TNF production and lethality in mice: effect of L-carnitine and some acyl derivatives. Mediators Inflamm 2:S43-S50. (Pubitemid 23324384)
40. Sawai T, Drongowski RA, Lampman RW, Coran AG, Harmon CM. 2001. The effect of phospholipids and fatty acids on tight-junction permeability and bacterial translocation. Pediatr Surg Int 17:269-274. (Pubitemid 32487930)
41. Shanmuganayagam D, Beahm MR, Osman HE, Krueger CG, Reed JD, Folts JD. 2002. Grape seed and grape skin extracts elicit a greater antiplatelet effect when used in combination than when used individually in dogs and humans. J Nutr 132:3592-3598. (Pubitemid 35435033)
42. Tsao FH, Shanmuganayagam D, Zachman DK, Khosravi M, Folts JD, Meyer KC. 2007. A continuous fluorescence assay for the determination of calcium-dependent secretory phospholipase A2 activity in serum. Clin Chim Acta 379:119-126. (Pubitemid 46366979)
43. Ullman-Cullere MH, Foltz CJ. 1999. Body condition scoring: a rapid and accurate method for assessing health status in mice. Lab Anim Sci 49:319-323. (Pubitemid 29284390)
44. 2 in the pathogenesis of the hemodynamic changes in endotoxin shock. Can J Physiol Pharmacol 61:561-566.
45. 2 activation is the pivotal step in the effector pathway of inflammation. Adv Exp Med Biol 275:83-101.
46. 2 secretion is a common effector pathway of interleukin 1 and tumour necrosis factor action. Immunol Lett 28:187-193.
47. Watterson C, Lanevschi A, Horner J, Louden C. 2009. A comparative analysis of acute-phase proteins as inflammatory biomarkers in preclinical toxicology studies: implications for preclinical to clinical translation. Toxicol Pathol 37:28-33.
48. 2 enzymes in atherogenesis. Curr Opin Lipidol 16:341-344.
49. Williamson G, Manach C. 2005. Bioavailability and bioefficacy of polyphenols in humans. H. Review of 93 intervention studies. Am J Clin Nutr 81:243S-255S.
50. 2. Shock 30:206-211.